A no-effect dose for female reproductive toxicity in rats was not established. Pregabalin, at concentrations that were, in general, 10-times those attained in clinical trials, does not inhibit human CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 enzyme systems. In vitro drug interaction studies demonstrate that pregabalin does not induce CYP1A2 or CYP3A4 activity. Therefore, an increase in the metabolism of coadministered CYP1A2 substrates (e.g. theophylline, caffeine) or CYP 3A4 substrates (e.g., midazolam, testosterone) is not anticipated.
- Also, tell your doctor right away about muscle pain or problems along with feeling sick and feverish, or any changes in your eyesight, including blurry vision or if you have any kidney problems or get dialysis.
- The following adverse reactions have been identified during postapproval use of LYRICA.
- Table 12 shows median baseline seizure rates, median percent change from baseline in seizure rates, and percent difference relative to placebo (derived from the primary analysis model) by dose.
- Also, tell your doctor right away about muscle pain or problems along with feeling sick and feverish or any changes in your eyesight, including blurry vision or if you have any kidney problems or get dialysis.
- In a phase 2 study, the medication showed up to 20% average weight loss at 52 weeks for people with obesity or overweight without diabetes and 17% for those with overweight/obesity and type 2 diabetes.
Medicare policies and claim forms
LYRICA is contraindicated in patients with known hypersensitivity to pregabalin or any of its components. Angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin price usa pregabalin therapy see Warnings and Precautions (5.2). View documents regarding our prescription coverage policies, reimbursement and claim forms for Medicare. Explore ways to find Humana’s list of covered drugs and their costs.